1.79

4.28% -0.08

Beyondspring Inc (BYSI)

Overview News Price History Option Chain Discussions Forecast

Beyondspring Inc stock is traded at $1.79, with a volume of 22,246. It is down -4.28% in the last 24 hours and up +4.68% over the past month. BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Previous Close:

$1.87

Open:

$1.78

24h Volume:

22,246

Relative Volume:

1.17

Market Cap:

$73.60M

Revenue:

$1.88M

Net Income/Loss:

$-8.48M

P/E Ratio:

-9.5162

EPS:

-0.1881

Net Cash Flow:

$-19.13M

1W Performance:

+0.00%

1M Performance:

+4.68%

6M Performance:

+19.33%

1Y Performance:

-19.73%

1-Day Range:

$1.7201

$1.8799

1-Week Range:

$1.6862

$1.92

52-Week Range:

$1.175

$2.44

Beyondspring Inc Stock (BYSI) Company Profile

Name

Beyondspring Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

646-528-4184

Address

100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY

Employee

Twitter

@BeyondSpringInc

Next Earnings Date

2026-08-12

Latest SEC Filings

BYSI's Discussions on Twitter

Compare BYSI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BYSI Beyondspring Inc	1.79	71.96M	1.88M	-8.48M	-19.13M	-0.1881
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Beyondspring Inc Stock (BYSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-21	Downgrade	BofA Securities	Buy → Underperform
Dec-02-21	Downgrade	Jefferies	Buy → Hold
Dec-01-21	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-01-21	Downgrade	William Blair	Outperform → Mkt Perform
Sep-09-21	Initiated	Robert W. Baird	Outperform
Aug-04-21	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-05-21	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-21	Initiated	BofA Securities	Buy
Dec-29-20	Initiated	Evercore ISI	Outperform
Feb-07-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	Nomura	Buy
Dec-03-19	Initiated	William Blair	Outperform
Jul-10-19	Reiterated	H.C. Wainwright	Buy
Apr-30-19	Downgrade	Maxim Group	Buy → Hold
Oct-25-18	Reiterated	Maxim Group	Buy

View All

Beyondspring Inc Stock (BYSI) Latest News

Jun 29, 2026

BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan

Jun 29, 2026

BeyondSpring Inc.(NasdaqCM: BYSI) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 27, 2026

BYSI Q1 2026 Earnings: Narrowing Losses Amid Pipeline Progress, Stock Gains 5.6%Pre-Earnings Drift - dars.gov.et

Jun 27, 2026